$HCXY

Hercules Capital Announces Date of 2026 Annual Meeting of Stockholders

Hercules Capital, Inc. (NYSE: HTGC) will hold its 2026 Annual Meeting of Stockholders virtually on Thursday, June 18, 2026, at 9:00 a.m. Eastern Time. Stockholders will vote on matters including the election of an independent director, executive officer compensation, equity incentive plan amendments, and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm. The proxy statement was filed on April 23, 2026.

Original reporting
Published May 7, 2026, 1:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 7, 2026, 2:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Hercules Capital Announces Date of 2026 Annual Meeting of Stockholders — source image
Decision brief

The 30-second read

$HCXYNeutralLow
01

Why it matters

The scheduled annual meeting is a standard governance event with limited immediate market impact but may influence investor sentiment if significant proposals are discussed.

02

Market read

The event is routine with low immediate trading impact but is relevant for long-term shareholders and those closely following the company's governance.

03

What to watch

Unforeseen proposals or shareholder activism could introduce volatility; monitoring proxy statements for specific agenda items is advisable.

Relevance 6/10Timing: medium-term (scheduled for June 18, 2026)

Background

Hercules Capital is a specialty finance company focusing on venture debt and equity investments.

Company-level read

Ticker impact

$HCXYNeutralMedium confidence
Context

The news pertains to Hercules Capital's upcoming annual meeting, which may influence investor sentiment and stock performance.

Expected impact

Minimal short-term price movement expected; potential for slight positive sentiment if proposals are well-received.

Evidence & confidence

Annual meetings are standard events; unless significant proposals are contested, market reaction is typically limited.

Market effects

Limited; the event is specific to Hercules Capital and unlikely to influence broader sector trends.

Minimal; the event is domestic and scheduled well in advance.

negligible; the event does not have global implications.

Counterpoint

Some investors might interpret the scheduled meeting as an opportunity to influence company policies positively, potentially leading to a favorable outlook.

Key entities

  • Hercules Capital, Inc.

    A specialty finance company providing capital to venture-backed companies.

Related articles

$HCXYMed

Hercules Capital Reports Second Quarter 2026 Financial Results

Hercules Capital, Inc. (HCXY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hercules Capital Reports Second Quarter 2026 Financial Results Record 1H 2026 Total New Debt and Equity Commitments of $2.74 Billion, an Increase of 35.6% Year-over-Year Record 1H 2026 Total Fundings of $1.35 Billion, an Increase of 8.5% Year-over-Year Record 1H 2026

$HCXYMed

Hercules Capital, Inc. (HCXY): Results of Operations and Financial Condition

Hercules Capital, Inc. (HCXY) filed an SEC Form 8-K — Results of Operations and Financial Condition. htgc-20260721 0001280784 false 0001280784 2026-07-21 2026-07-21 0001280784 htgc:CommonStockParValueZeroPointZeroZeroOnePerShareMember 2026-07-21 2026-07-21 0001280784 htgc:SixPointTwoFiveNotesDueTwoThousandThirtyThreeMember 2026-07-21 2026-07-21 UNITED STATES SECURITIES AND EXCHA

Low

Nous Research $90M Raise: NVIDIA’s Dual Bet Reveals the Compute Landlord Strategy

NVIDIA is investing in both proprietary and open-source AI models, including a $90M Series B round for Nous Research, valuing it at $1.5B. Nous claims its Hermes 4.3 model outperforms GPT-4o in key metrics, but lacks independent verification. The company aims to compete with lower pricing, offering $0.30 per million tokens compared to competitors' higher rates. NVIDIA's strategy ensures its hardware remains central to AI infrastructure regardless of the winning model architecture.

$BHVNMed

Biohaven Licenses IgG Degrader Portfolio To Ono Pharma In Key Asian Markets

Biohaven (BHVN) has licensed its IgG degrader portfolio to Ono Pharma for Asian markets, including Japan and South Korea. The deal includes up to $100M in payments, with Biohaven retaining rights outside these regions. The portfolio, led by BHV-1300 in Phase 3 trials for Graves' disease, aims to treat autoimmune disorders. Biohaven's stock closed at $11.88, up 1.18% in pre-market trading.

$BAMed

NASA to pump hundreds of millions more tax dollars into troubled Boeing Starliner

NASA plans to invest $359 million more in Boeing's Starliner capsule for ISS missions, despite technical issues. The agency aims to send an unmanned Starliner to the ISS by late 2027, with a manned mission possible in 2028. The ISS is set to retire by 2030. SpaceX's Dragon Crew is noted as a cheaper, more reliable alternative. NASA insists on having two providers for ISS missions. Dr. Ken Kremer, a space expert, highlights the high stakes of maintaining a presence in low Earth orbit.